Biotech firm Precision Autoimmune Therapeutics, specializing in the research and development of innovative drugs for autoimmune diseases, will focus on the precise therapies of autoimmune diseases.
Precision Autoimmune Therapeutics (Chinese: 天石同达 ) announced its completion of an Angel financing round worth CNY 140 million (USD 20.9 million). The round was led by Emerging Technology Partners (Chinese: ETP致和道康基金) and Redhill Capital (Chinese: 丹麓资本), with strategic investment from CASI Pharmaceuticals (Chinese: 凯信远达).
This round will be used to accelerate the declaration of US-China clinical trials of the company's product in research PAT-A001 and expand the deployment of its precision typing platform HDPM, in order to develop more novel therapies of autoimmune diseases and inflammatory diseases.
Founded in 2022, Precision Autoimmune Therapeutics is the first company of innovative drugs in China which focuses on the research and development of autoimmune diseases based on its precision typing platform HDPM. Working with internationally renowned experts in the fields of immunology, precision medicine and artificial intelligence, Precision Autoimmune Therapeutics deeply integrates multi-omics technology, single-cell technology and big data analysis to improve the R&D success rate of innovative drugs for autoimmune diseases.
The company's competitors include RemeGen (Chinese: 荣昌生物), Harbour BioMed (Chinese: 和铂医药) and Innocare (Chinese: 诺诚健华).